about
Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus ErythematosusU1-RNP and TLR receptors in the pathogenesis of mixed connective tissue diseasePart I. The U1-RNP complex and its biological significance in the pathogenesis of mixed connective tissue diseaseImmunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndromePersonalized medicine in rheumatologyIL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease.Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid ArthritisFLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis.U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue diseasePart II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease.RORC2 Genetic Variants and Serum Levels in Patients with Rheumatoid ArthritisDiscrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP.The role of cell-free circulating microRNA in diagnostics in patients with rheumatoid arthritis.Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12.The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Association of HLA-DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients.Interleukin-21 gene polymorphism rs2221903 is associated with disease activity in patients with rheumatoid arthritis.Cytokines in the pathogenesis of hemophilic arthropathy.Histamine releasing factor (HRF) in pannus of joints affected by rheumatoid arthritis.CD28, CTLA-4 and CCL5 gene polymorphisms in patients with rheumatoid arthritis.Epigenetics: The Future Direction in Systemic Sclerosis.HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case-control study.Association of the Smad3 and NFATc2 gene polymorphisms and their serum levels with susceptibility to rheumatoid arthritis in Polish cohorts.Genetic Variants in IL-12B and IL-27 in the Polish Patients with Systemic Lupus Erythematosus.Lack of association between rheumatoid arthritis and genetic variants rs10889677, rs11209026 and rs2201841 of IL-23R gene.IL-12B Gene Polymorphisms and IL-12 p70 Serum Levels Among Patients with Rheumatoid Arthritis.Impact of the IL-17F, IL-23 and IL-23R on susceptibility and phenotype of systemic lupus erythematosus.Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients.Lack of significant association between selected STAT3 polymorphisms and rheumatoid arthritis in the Polish population.polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patientsAssociation between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA)[Influence of genetic factors on development and severity of rheumatoid arthritis--part II]Interleukin 1 beta (IL1beta) gene polymorphisms (SNP-511 and SNP+3953) in Hashimoto's thyroiditis among the Polish populationGenetic polymorphisms of Foxp3 in patients with rheumatoid arthritisAssociation of single nucleotide polymorphisms in the IL27 gene with rheumatoid arthritisThe Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus ErythematosusInterferons (IFN-A/-B/-G) Genetic Variants in Patients with Mixed Connective Tissue Disease (MCTD)KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid ArthritisThe Serum Cell-Free microRNA Expression Profile in MCTD, SLE, SSc, and RA PatientsIL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases
P50
Q26782454-83198C89-DC55-47C9-AD97-D2C74E8ACE80Q27006881-F2A9D90D-8C9A-4D37-BF77-0E167C6EBCE5Q28071723-1CFB5DAD-CA0C-4E52-A6F4-A9B45D674665Q28077413-18D07C30-7F28-4111-980F-8574D9353322Q33417336-BFB8549D-8F85-4EBF-AE00-B1AB23B3E126Q36101506-06E3E467-1EF8-4CDD-B0CE-74517EA25965Q36316634-90846128-F420-45DE-B59E-42C75D079E32Q36842417-39F11F17-CEFB-46C2-A1BB-D5CA7D40BD11Q36847004-5D1EE412-E7BA-4A1E-99C1-6E64534C3E33Q37140622-C92FFAB6-D8A4-4C80-9548-E13E6F4D6866Q37141415-91243C90-DBEE-4761-B7A6-52221EA642BDQ38086376-86FDCE09-D07A-4F34-9828-65A85BDC51B4Q38648460-28F32627-0D8F-45FA-A2D6-68FEB0686554Q40947113-21FE2CC0-9780-407E-8BA8-4FDA937DB3A2Q41549665-A608C2B2-EE55-4BEC-9A41-40FC24D2563CQ45874704-16A18080-24E0-4B39-87C0-54D7CA36EBADQ46697965-D2A80D57-D32A-4FA4-B023-943C509DC822Q47914962-926A09D7-0E78-43D3-8C67-DD0FB76A0ED9Q47939031-B9B4AC0E-81C0-45BF-BCEE-A2332394C9CDQ48093446-1FDF09FC-4119-4772-A351-3C6F4F36F6A9Q48812509-FFA87BC2-A5EF-4D5E-B45F-84B4F8BCEA35Q48830116-D8AC1499-6FD3-4B31-804E-6EDAC94FFC2FQ49686397-6806D3BA-B4AF-43C5-85A6-45A1EEAED71EQ51298173-FB8AE930-D6A9-4FEC-ACB8-1FB3BDC64635Q51694777-C5C92C3B-CEDE-4DC1-B068-D3D0D8D18902Q52665701-BD82FB32-C84F-45EC-80FE-346FF3BD7283Q53819679-140A56B7-FBE2-446F-8FD3-51B0230C6ADCQ54427789-7958CDCD-5DD9-4AC3-9649-AFD68A11F4C3Q55208964-007C4934-4256-4C88-9857-BFE75CC26805Q64092329-43F449BE-6EA0-470C-9D1C-DBF87892FDFBQ84553425-2114C2E1-5B84-4F8C-B90E-A646571A9731Q84783292-6E272FF8-8E30-490D-95F9-2BB1E57BE96FQ85770526-128D7F2F-C848-4122-8E22-878E72027D98Q86109569-C8B48BF4-1A23-4777-B28E-954F7AF73007Q87415793-94DC9D9C-7E03-48A1-9AE3-5667C8901E2BQ90663826-ED4CD95B-7AAA-4D67-9418-D429E2F3FFDEQ91444812-EDC43EA4-672F-4A97-8FF7-522ACC9C4F96Q92570188-0AACE941-2508-485B-95EA-E943379029D0Q92631956-ED9FD966-0955-4472-B3CA-2FA87CF3195EQ92966518-6EF9F124-BE66-4B05-80B4-F32E5EFC7869
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-4249-3136
@en
name
Agnieszka Paradowska-Gorycka
@ast
Agnieszka Paradowska-Gorycka
@en
Agnieszka Paradowska-Gorycka
@es
Agnieszka Paradowska-Gorycka
@nl
Agnieszka Paradowska-Gorycka
@pl
type
label
Agnieszka Paradowska-Gorycka
@ast
Agnieszka Paradowska-Gorycka
@en
Agnieszka Paradowska-Gorycka
@es
Agnieszka Paradowska-Gorycka
@nl
Agnieszka Paradowska-Gorycka
@pl
prefLabel
Agnieszka Paradowska-Gorycka
@ast
Agnieszka Paradowska-Gorycka
@en
Agnieszka Paradowska-Gorycka
@es
Agnieszka Paradowska-Gorycka
@nl
Agnieszka Paradowska-Gorycka
@pl
P106
P1153
35604549300
P1559
Agnieszka Paradowska-Gorycka
@pl
P21
P214
70152682555023312087
P31
P3124
P496
0000-0002-4249-3136
P735
P7859
viaf-70152682555023312087